News Novartis AG

Stocks

NOVN

CH0012005267

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 05:10:46 2026-06-15 am EDT			5-day change	1st Jan Change
121.89 ^CHF	-0.16%		+3.73%	+11.06%

Jun. 12	Analyst recommendations: Adobe, CME Group, Nvidia, Flutter…
Jun. 12	Novartis' Rhapsido Meets Primary Endpoints in Chronic Inducible Urticaria Trial	MT

All News

Mentions Relevance

Jun. 12	Novartis' Rhapsido Meets Primary Endpoints in Chronic Inducible Urticaria Trial	MT
Jun. 12	Novartis RemIND data at EAACI show Rhapsido(R) potential as first targeted therapy for chronic inducible urticaria (CIndU)	DJ
Jun. 12	Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)	GL
Jun. 12	Novartis AG Presents RemIND Data At EAACI Demonstrating Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria	CI
Jun. 12	Swiss stocks - Factors to watch on June 12	RE
Jun. 12	Swiss pharma hub Basel frets over population cap threat	RE
Jun. 11	Novartis says rare muscle disease drug shows promise in early trial	RE
Jun. 11	Novartis AG Announces Phase I/II Study Results For Delpacibart Braxlosiran In Facioscapulohumeral Muscular Dystrophy	CI
Jun. 11	Novartis Says Early-to-Mid Stage Study for Muscular Dystrophy Drug Meets Main Goal	MT
Jun. 11	NOVARTIS AG : Jefferies remains Neutral	ZD
Jun. 11	Novartis Reports Positive Biomarker Data for Del-Brax in Muscular Dystrophy Study	MT
Jun. 11	Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint	DJ
Jun. 11	Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint	GL
Jun. 09	NOVARTIS AG : Deutsche Bank remains its Buy rating	ZD
Jun. 08	Novartis to highlight Rhapsido(R) data across multiple immune-mediated diseases at EAACI Congress 2026	DJ
Jun. 08	Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026	GL
Jun. 08	Businesses fear for economy if Swiss vote to cap population at 10 million	RE
Jun. 04	Novartis Reports Final 2.5-Year Phase III ALIGN Results Showing Slower Kidney Function Decline With Vanrafia Versus Placebo In Adults With IgA Nephropathy	CI
Jun. 04	Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia(R) over 2.5 years	DJ
Jun. 04	Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years	GL
Jun. 04	NOVARTIS AG : Jefferies gives a Neutral rating	ZD
Jun. 03	Novartis Says Cosentyx Shows Sustained Remission in Phase 3 Trial	MT
Jun. 03	Novartis Cosentyx(R) PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients	DJ
Jun. 03	Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients	GL
Jun. 03	Novartis Presents New Cosentyx Data In Polymyalgia Rheumatica Demonstrating Statistically Significant Clinically Meaningful Difference In Sustained Remission Rates Versus Placebo And Significant Steroid Sparing	CI